Healthcare professionals (HCPs) face difficulty in predicting the progression of disease in COVID-19 patients. A recent study conducted at Yale University has suggested that blood biomarkers can predict the COVID-19 severity and outcomes among patients. In a cross-sectional and longitudinal cohort study, plasma proteome profiling of more than 3300 COVID-19 hospitalized patients helped identify the biomarkers associated with severe disease progression.
The study emphasized the role of neutrophil activation in the pathogenesis of severe COVID-19. Using artificial intelligence (AI), the researchers found that neutrophil activation, along with elevated levels of associated proteins (resistin, lipocalin-2, hepatocyte growth factor, interleukin-8, and granulocyte colony-stimulating factor), were strong predictors of disease severity. Researchers observed that COVID-19 patients with…
